Guggenheim Capital LLC Has $736,000 Stock Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Guggenheim Capital LLC lifted its stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) by 141.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 19,078 shares of the company's stock after purchasing an additional 11,180 shares during the quarter. Guggenheim Capital LLC's holdings in Protagonist Therapeutics were worth $736,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at $38,000. Covestor Ltd lifted its stake in Protagonist Therapeutics by 5,200.0% in the 4th quarter. Covestor Ltd now owns 1,643 shares of the company's stock worth $63,000 after acquiring an additional 1,612 shares in the last quarter. KBC Group NV boosted its position in Protagonist Therapeutics by 54.4% during the 4th quarter. KBC Group NV now owns 2,093 shares of the company's stock worth $81,000 after acquiring an additional 737 shares during the period. Nisa Investment Advisors LLC grew its stake in Protagonist Therapeutics by 10.4% during the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company's stock valued at $121,000 after acquiring an additional 295 shares in the last quarter. Finally, Cibc World Markets Corp acquired a new position in shares of Protagonist Therapeutics in the 4th quarter valued at about $211,000. Hedge funds and other institutional investors own 98.63% of the company's stock.

Protagonist Therapeutics Stock Performance

Shares of PTGX traded down $0.10 during trading hours on Monday, hitting $44.39. 592,255 shares of the company were exchanged, compared to its average volume of 856,212. The firm's 50 day moving average is $45.58 and its 200-day moving average is $42.84. Protagonist Therapeutics, Inc. has a 52 week low of $24.78 and a 52 week high of $60.60. The company has a market cap of $2.72 billion, a PE ratio of 16.69 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last announced its quarterly earnings results on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $170.64 million for the quarter, compared to the consensus estimate of $56.65 million. As a group, equities analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Insider Activity at Protagonist Therapeutics

In other Protagonist Therapeutics news, CFO Asif Ali sold 24,903 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $58.73, for a total value of $1,462,553.19. Following the sale, the chief financial officer now owns 62,821 shares of the company's stock, valued at $3,689,477.33. This trade represents a 28.39 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director William D. Waddill sold 4,000 shares of Protagonist Therapeutics stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the transaction, the director now directly owns 13,130 shares in the company, valued at approximately $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,532 shares of company stock worth $3,665,786. 5.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PTGX shares. JPMorgan Chase & Co. raised their price target on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a report on Tuesday, March 4th. BMO Capital Markets boosted their price target on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the company an "outperform" rating in a report on Tuesday, March 11th. HC Wainwright reiterated a "buy" rating and set a $80.00 price objective on shares of Protagonist Therapeutics in a report on Thursday, April 10th. JMP Securities restated a "market outperform" rating and issued a $58.00 target price on shares of Protagonist Therapeutics in a research note on Friday, February 7th. Finally, The Goldman Sachs Group dropped their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research report on Monday, February 24th. Two equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Protagonist Therapeutics presently has a consensus rating of "Moderate Buy" and an average price target of $65.44.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.